Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Maze Therapeutics, Inc.NASDAQ: MAZE
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 16.8% from a year ago
Property, plant & equipment (net) stood at $23.97M at the end of Q1 FY2026, down 16.8% from a year earlier and down 4.7% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Property, plant & equipment (net) amounted to 5.7% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -16.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 25.16M USD
- Year-over-year change
- -15.9%
- 3-year CAGR
- -15.2%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.16M | -15.9% |
| FY2024 | 2024-12-31 | 29.92M | -14.5% |
| FY2023 | 2023-12-31 | 34.98M | -15.1% |
| FY2022 | 2022-12-31 | 41.23M | — |
Property, Plant & Equipment (Net) vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -16.8% is the 5th highest of 8, against a peer median of -10.4%.
- Property, plant & equipment (net) amounts to 5.7% of total assets for MAZE, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $126.27M USD | +11.4% | -8.2% | 3.9% | |
| Mar 2026 | $23.97M USD | -16.8% | -15.2% | 5.7% | |
SEPNSepterna, Inc. | Sep 2026 | $23.61M USD | -10.4% | +102.9% | 3.8% |
| Sep 2026 | $10.53M USD | -33.3% | -21.4% | 1.2% | |
| Mar 2026 | $6.44M USD | +20.6% | -12.8% | 1.3% | |
BIOABioAge Labs, Inc. | Mar 2026 | $3.8M USD | -8.0% | +115.6% | 1.0% |
| Dec 2025 | €2.98M EUR | -40.5% | -26.1% | 1.2% | |
| Mar 2026 | $317K USD | -22.3% | -15.2% | 0.6% | |
| Peer median (excluding MAZE) | — | -10.4% | -12.8% | 1.2% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.